Stonepine Capital Management LLC Cuts Stock Position in Evolus, Inc. (NASDAQ:EOLS)

Stonepine Capital Management LLC cut its position in Evolus, Inc. (NASDAQ:EOLS) by 7.7% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,264,651 shares of the company’s stock after selling 105,170 shares during the quarter. Evolus comprises 11.3% of Stonepine Capital Management LLC’s holdings, making the stock its 2nd biggest position. Stonepine Capital Management LLC owned approximately 2.00% of Evolus worth $13,962,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Tang Capital Management LLC lifted its position in Evolus by 3.1% in the 4th quarter. Tang Capital Management LLC now owns 4,997,399 shares of the company’s stock valued at $55,171,000 after purchasing an additional 150,000 shares during the last quarter. Nantahala Capital Management LLC lifted its position in Evolus by 10.8% in the 4th quarter. Nantahala Capital Management LLC now owns 3,130,149 shares of the company’s stock valued at $34,557,000 after purchasing an additional 305,300 shares during the last quarter. Caligan Partners LP lifted its position in Evolus by 22.7% in the 4th quarter. Caligan Partners LP now owns 2,692,388 shares of the company’s stock valued at $29,724,000 after purchasing an additional 498,900 shares during the last quarter. Millennium Management LLC lifted its position in Evolus by 29.1% in the 4th quarter. Millennium Management LLC now owns 1,368,423 shares of the company’s stock valued at $15,107,000 after purchasing an additional 308,753 shares during the last quarter. Finally, Boothbay Fund Management LLC lifted its position in Evolus by 30.9% in the 4th quarter. Boothbay Fund Management LLC now owns 1,287,767 shares of the company’s stock valued at $14,217,000 after purchasing an additional 304,065 shares during the last quarter. 90.69% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have commented on EOLS shares. BTIG Research started coverage on shares of Evolus in a research report on Thursday, April 17th. They set a “buy” rating and a $21.00 price target on the stock. Barclays boosted their price target on shares of Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. HC Wainwright restated a “buy” rating and set a $27.00 price target on shares of Evolus in a research report on Thursday, April 10th. Finally, Needham & Company LLC restated a “buy” rating and set a $22.00 price target on shares of Evolus in a research report on Thursday, May 8th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Evolus currently has a consensus rating of “Buy” and an average price target of $23.75.

Evolus Stock Down 3.0%

EOLS stock opened at $9.70 on Friday. Evolus, Inc. has a 52 week low of $8.67 and a 52 week high of $17.82. The company has a market capitalization of $625.42 million, a price-to-earnings ratio of -10.66 and a beta of 1.11. The firm’s 50-day moving average is $11.32 and its two-hundred day moving average is $12.33. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58.

Insider Transactions at Evolus

In other news, CFO Sandra Beaver sold 8,996 shares of Evolus stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $119,286.96. Following the transaction, the chief financial officer now owns 173,583 shares of the company’s stock, valued at $2,301,710.58. The trade was a 4.93% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider David Moatazedi sold 6,251 shares of Evolus stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $12.40, for a total transaction of $77,512.40. Following the completion of the transaction, the insider now directly owns 508,619 shares in the company, valued at $6,306,875.60. This represents a 1.21% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 86,241 shares of company stock valued at $1,048,666 in the last quarter. Insiders own 5.90% of the company’s stock.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.